CE2026-03-31T11:24:00
Source: https://www.shutterstock.com/image-illustration/3d-rendering-mitochondrion-powerhouse-cell-intertwin
Authorisation of the small molecule therapy in the EU represents a new option for thymidine kinase 2 deficiency, builds on earlier US FDA approval.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-06-29T06:00:00
Sponsored by Lubrizol Advanced Materials Europe BV
2026-07-13T07:00:00
Sponsored by Thermo Fisher Scientific
2026-04-30T10:37:00
Sponsored by Shimadzu
Site powered by Webvision Cloud